Review



cobra venom factor cvf  (Quidel)


Bioz Verified Symbol Quidel is a verified supplier
Bioz Manufacturer Symbol Quidel manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Quidel cobra venom factor cvf
    (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and <t>Cobra</t> <t>venom</t> <t>factor</t> <t>(CVF)</t> treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.
    Cobra Venom Factor Cvf, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 225 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cobra+venom+factor+cvf/Cobra+Venom+Factor/bio_rxiv__64898__2026__03__16__712023-265-12-16
    Average 96 stars, based on 225 article reviews
    cobra venom factor cvf - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Neutrophils are critical for placental and fetal infection with the human pathogen Listeria monocytogenes"

    Article Title: Neutrophils are critical for placental and fetal infection with the human pathogen Listeria monocytogenes

    Journal: bioRxiv

    doi: 10.64898/2026.03.16.712023

    (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and Cobra venom factor (CVF) treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.
    Figure Legend Snippet: (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and Cobra venom factor (CVF) treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.

    Techniques Used: Labeling, Comparison, Isolation, Infection, Blocking Assay, Combined Bisulfite Restriction Analysis Assay, Control

    Related Articles

    Concentration Assay:

    Article Title: Antioxidase-mimetic artificial biotubes for anti-inflammatory healing and regeneration of vascular injury.
    Article Snippet: Inflammation is a major obstacle to endothelialization, which is essential to the long-term functionality of cardiovascular implants.. Developing efficient antioxidant and inflammation-modulating biotubes for endothelial repair with minimal postsurgical complications represents a compelling clinical challenge.. Here, we present the design of an antioxidase-mimic modified artificial biotube (RNP) by integrating Ru cluster-anchored Ni-based metal-organic framework onto a polycaprolactone fiber scaffold.

    Article Title: Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding
    Article Snippet: The levels of C3a and C5b-9 generation were measured by ELISA (Complement C3a Human ELISA Kit, Fisher scientific, USA; Complement C5b-9 Human ELISA Kit, Quidel, San Diego, CA, USA) in human whole blood anticoagulated by hirudin (300 IU/mL of blood, HYPHEN BioMed) and sodium citrate synergistically. .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation). .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation).

    Activation Assay:

    Article Title: Antioxidase-mimetic artificial biotubes for anti-inflammatory healing and regeneration of vascular injury.
    Article Snippet: Inflammation is a major obstacle to endothelialization, which is essential to the long-term functionality of cardiovascular implants.. Developing efficient antioxidant and inflammation-modulating biotubes for endothelial repair with minimal postsurgical complications represents a compelling clinical challenge.. Here, we present the design of an antioxidase-mimic modified artificial biotube (RNP) by integrating Ru cluster-anchored Ni-based metal-organic framework onto a polycaprolactone fiber scaffold.

    Article Title: Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding
    Article Snippet: The levels of C3a and C5b-9 generation were measured by ELISA (Complement C3a Human ELISA Kit, Fisher scientific, USA; Complement C5b-9 Human ELISA Kit, Quidel, San Diego, CA, USA) in human whole blood anticoagulated by hirudin (300 IU/mL of blood, HYPHEN BioMed) and sodium citrate synergistically. .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation). .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation).

    Combined Bisulfite Restriction Analysis Assay:

    Article Title: Antioxidase-mimetic artificial biotubes for anti-inflammatory healing and regeneration of vascular injury.
    Article Snippet: Inflammation is a major obstacle to endothelialization, which is essential to the long-term functionality of cardiovascular implants.. Developing efficient antioxidant and inflammation-modulating biotubes for endothelial repair with minimal postsurgical complications represents a compelling clinical challenge.. Here, we present the design of an antioxidase-mimic modified artificial biotube (RNP) by integrating Ru cluster-anchored Ni-based metal-organic framework onto a polycaprolactone fiber scaffold.

    Article Title: Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis
    Article Snippet: .. Cobra venom factor (CVF) was purchased from Quidel and eculizumab (Soliris) was obtained from remnants of infusions. .. TSP-5 was obtained from R&D (3134-CPB).

    Article Title: Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding
    Article Snippet: The levels of C3a and C5b-9 generation were measured by ELISA (Complement C3a Human ELISA Kit, Fisher scientific, USA; Complement C5b-9 Human ELISA Kit, Quidel, San Diego, CA, USA) in human whole blood anticoagulated by hirudin (300 IU/mL of blood, HYPHEN BioMed) and sodium citrate synergistically. .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation). .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation).

    Article Title: C-reactive protein is a broad-spectrum capsule-binding receptor for hepatic capture of blood-borne bacteria
    Article Snippet: Desthiobiotin , IBA Lifesciences GmbH , Cat# 2-1000-002. .. Cobra venom factor (CVF) , Quidel , Cat# A600. .. TMB chromogenic substrate , Tiangen , Cat# PA107.

    Article Title: Neutrophils are critical for placental and fetal infection with the human pathogen Listeria monocytogenes
    Article Snippet: After gentamicin (100 μg/ml) (Sigma) treatment, samples were washed, fixed with 1.5 % PFA (Merck) and intracellular bacterial burden quantified with a CytoFLEX S cytometer and FlowJo analysis software. .. Prior to Listeria opsonization, human serum was de-complemented using 12 μg of cobra venom factor (CVF) (Quidel, San Diego, USA) per 500 μl of extracted serum and incubated for 1 h at 37 °C ( ). .. CFSE (Invitrogen) stained Listeria was used to infect isolated neutrophils (MOI8) opsonized with CVF (Quidel) treated serum, untreated serum, and HBSS (Merck) as a control.

    Article Title: Spatial Transcriptomic Analysis Reveals Increased Adipogenesis and Triggering of the Non-Alcoholic Fatty Liver Disease Pathway in Pig-to-NHP Islet Recipients' livers During the Early Post-xenotransplant Period.
    Article Snippet: .. Cobra venom factor (CVF) (100 U/kg, Quidel, San Diego, CA) was administered i.v. on Day −1 of the transplant to deplete the complement proteins. .. TNFα neutralizing mAb, adalimumab (Humira, Abbott Laboratories, Queensborough, UK) was administered subcutaneously 2–3 h before islet infusion at a dose of 5 mg/kg.

    Article Title: Protection against Neisseria meningitidis nasopharyngeal colonization relies on antibody opsonization and phagocytosis by neutrophils
    Article Snippet: .. Complement depletion was achieved through injection of 20 μg of Cobra Venom Factor (CVF) (Quidel) in 200 μL of PBS 24 hours prior to infection ( ). ..

    Article Title: Thrombospondin-1 inhibits alternative complement pathway activation in vasculitis synergistically to factor H
    Article Snippet: .. Cobra venom factor (CVF) was purchased from Quidel, and Eculizumab (Soliris) as well as Pegcetacoplan (Aspaveli) was obtained from remnants of infusions. .. TSP-5 was obtained from R&D.

    Positive Control:

    Article Title: Antioxidase-mimetic artificial biotubes for anti-inflammatory healing and regeneration of vascular injury.
    Article Snippet: Inflammation is a major obstacle to endothelialization, which is essential to the long-term functionality of cardiovascular implants.. Developing efficient antioxidant and inflammation-modulating biotubes for endothelial repair with minimal postsurgical complications represents a compelling clinical challenge.. Here, we present the design of an antioxidase-mimic modified artificial biotube (RNP) by integrating Ru cluster-anchored Ni-based metal-organic framework onto a polycaprolactone fiber scaffold.

    Article Title: Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding
    Article Snippet: The levels of C3a and C5b-9 generation were measured by ELISA (Complement C3a Human ELISA Kit, Fisher scientific, USA; Complement C5b-9 Human ELISA Kit, Quidel, San Diego, CA, USA) in human whole blood anticoagulated by hirudin (300 IU/mL of blood, HYPHEN BioMed) and sodium citrate synergistically. .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation). .. After that, 8 mM of CaCl2 and 6 mM of MgCl2 (final concentration) were added to trigger the complement activation (which is not applied to condition 3), Cobra Venom Factor (CVF) was used as positive control (final concentration of 1 μg/mL, Quidel Corporation).

    Negative Control:

    Article Title: Antioxidase-mimetic artificial biotubes for anti-inflammatory healing and regeneration of vascular injury.
    Article Snippet: Inflammation is a major obstacle to endothelialization, which is essential to the long-term functionality of cardiovascular implants.. Developing efficient antioxidant and inflammation-modulating biotubes for endothelial repair with minimal postsurgical complications represents a compelling clinical challenge.. Here, we present the design of an antioxidase-mimic modified artificial biotube (RNP) by integrating Ru cluster-anchored Ni-based metal-organic framework onto a polycaprolactone fiber scaffold.

    Control:

    Article Title: Antioxidase-mimetic artificial biotubes for anti-inflammatory healing and regeneration of vascular injury.
    Article Snippet: Inflammation is a major obstacle to endothelialization, which is essential to the long-term functionality of cardiovascular implants.. Developing efficient antioxidant and inflammation-modulating biotubes for endothelial repair with minimal postsurgical complications represents a compelling clinical challenge.. Here, we present the design of an antioxidase-mimic modified artificial biotube (RNP) by integrating Ru cluster-anchored Ni-based metal-organic framework onto a polycaprolactone fiber scaffold.

    Incubation:

    Article Title: Neutrophils are critical for placental and fetal infection with the human pathogen Listeria monocytogenes
    Article Snippet: After gentamicin (100 μg/ml) (Sigma) treatment, samples were washed, fixed with 1.5 % PFA (Merck) and intracellular bacterial burden quantified with a CytoFLEX S cytometer and FlowJo analysis software. .. Prior to Listeria opsonization, human serum was de-complemented using 12 μg of cobra venom factor (CVF) (Quidel, San Diego, USA) per 500 μl of extracted serum and incubated for 1 h at 37 °C ( ). .. CFSE (Invitrogen) stained Listeria was used to infect isolated neutrophils (MOI8) opsonized with CVF (Quidel) treated serum, untreated serum, and HBSS (Merck) as a control.

    Injection:

    Article Title: Protection against Neisseria meningitidis nasopharyngeal colonization relies on antibody opsonization and phagocytosis by neutrophils
    Article Snippet: .. Complement depletion was achieved through injection of 20 μg of Cobra Venom Factor (CVF) (Quidel) in 200 μL of PBS 24 hours prior to infection ( ). ..

    Infection:

    Article Title: Protection against Neisseria meningitidis nasopharyngeal colonization relies on antibody opsonization and phagocytosis by neutrophils
    Article Snippet: .. Complement depletion was achieved through injection of 20 μg of Cobra Venom Factor (CVF) (Quidel) in 200 μL of PBS 24 hours prior to infection ( ). ..



    Similar Products

    recombinant cvf  (Hycult Biotech)
    94
    Hycult Biotech recombinant cvf

    Recombinant Cvf, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cobra+venom+factor+cvf/Cobra+Venom+Factor%2C+Recombinant/pmc13594428-15-0-3
    Average 94 stars, based on 1 article reviews
    recombinant cvf - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cobra venom factor cvf  (TargetMol)
    94
    TargetMol cobra venom factor cvf
    In vivo splenic DC-specific transfection of mRNA/H 18 NPs and in vitro protein corona analysis of mRNA/H 18 NPs. (A) EGFP protein expression in splenic cell subsets of C57BL/6J mice 24 h post intravenous injection of different formulations. (B) The top 5 most abundant plasma proteins adsorbed on mRNA/H 18 NPs (C3: Complement C3; Ighm: Immunoglobulin heavy constant mu; Hbat1: Alpha-globin; Itih4: Inter alpha-trypsin inhibitor, heavy chain 4; Cnn2: Calponin). (C) Heatmap plot of major proteins in the protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. PBS group was used as a negative control. (D) Quantification of major adsorbed protein categories of different formulations. (E) Complement C3 abundance in protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. (F) Bioluminescence images of major organs and (G) Quantification of total bioluminescence flux in the spleen from C57BL/6J mice 6 h after intravenous injection of mLuc/H 18 NPs (mLuc dose of 0.25 mg kg −1 ). Mice were pre-treated with <t>cobra</t> <t>venom</t> <t>factor</t> <t>(CVF)</t> or PBS. (H) Fluorescence quantification of Cy5 mRNA delivered by uncoated or complement C3-coated Cy5-mRNA/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. (I) Bioluminescence intensity of luciferase protein translated from mRNA delivered by uncoated or complement C3-coated mLuc/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. Data were shown as mean ± SD (n = 3).
    Cobra Venom Factor Cvf, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cobra+venom+factor+cvf/Cobra+Venom+Factor/pmc12926576-59-0-7
    Average 94 stars, based on 1 article reviews
    cobra venom factor cvf - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cobra venom factor cvf  (Quidel)
    96
    Quidel cobra venom factor cvf
    (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and <t>Cobra</t> <t>venom</t> <t>factor</t> <t>(CVF)</t> treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.
    Cobra Venom Factor Cvf, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cobra+venom+factor+cvf/Cobra+Venom+Factor/bio_rxiv__64898__2026__03__16__712023-265-12-16
    Average 96 stars, based on 1 article reviews
    cobra venom factor cvf - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cobra venom factor cvf quidel  (Quidel)
    96
    Quidel cobra venom factor cvf quidel
    (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and <t>Cobra</t> <t>venom</t> <t>factor</t> <t>(CVF)</t> treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.
    Cobra Venom Factor Cvf Quidel, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cobra+venom+factor+cvf/Cobra+Venom+Factor/pm41214213-340-32-36
    Average 96 stars, based on 1 article reviews
    cobra venom factor cvf quidel - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    complement inhibitor cobra venom factor cvf  (Quidel)
    96
    Quidel complement inhibitor cobra venom factor cvf
    (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and <t>Cobra</t> <t>venom</t> <t>factor</t> <t>(CVF)</t> treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.
    Complement Inhibitor Cobra Venom Factor Cvf, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cobra+venom+factor+cvf/Cobra+Venom+Factor/pmc12454665-96-29-42
    Average 96 stars, based on 1 article reviews
    complement inhibitor cobra venom factor cvf - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Journal: iScience

    Article Title: Carboxypeptidase M deficiency aggravates complement-induced lung injury

    doi: 10.1016/j.isci.2026.117463

    Figure Lengend Snippet:

    Article Snippet: Recombinant CVF , HycultBiotech , Cat. #HC4073.

    Techniques: Cell-Signaling, Recombinant, Reverse Transcription, RNAscope, Software

    In vivo splenic DC-specific transfection of mRNA/H 18 NPs and in vitro protein corona analysis of mRNA/H 18 NPs. (A) EGFP protein expression in splenic cell subsets of C57BL/6J mice 24 h post intravenous injection of different formulations. (B) The top 5 most abundant plasma proteins adsorbed on mRNA/H 18 NPs (C3: Complement C3; Ighm: Immunoglobulin heavy constant mu; Hbat1: Alpha-globin; Itih4: Inter alpha-trypsin inhibitor, heavy chain 4; Cnn2: Calponin). (C) Heatmap plot of major proteins in the protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. PBS group was used as a negative control. (D) Quantification of major adsorbed protein categories of different formulations. (E) Complement C3 abundance in protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. (F) Bioluminescence images of major organs and (G) Quantification of total bioluminescence flux in the spleen from C57BL/6J mice 6 h after intravenous injection of mLuc/H 18 NPs (mLuc dose of 0.25 mg kg −1 ). Mice were pre-treated with cobra venom factor (CVF) or PBS. (H) Fluorescence quantification of Cy5 mRNA delivered by uncoated or complement C3-coated Cy5-mRNA/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. (I) Bioluminescence intensity of luciferase protein translated from mRNA delivered by uncoated or complement C3-coated mLuc/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. Data were shown as mean ± SD (n = 3).

    Journal: Bioactive Materials

    Article Title: Splenic dendritic cell-targeting mRNA transfection of H-type ionizable lipid-based LNPs for enhancing tumor immunotherapy

    doi: 10.1016/j.bioactmat.2026.02.018

    Figure Lengend Snippet: In vivo splenic DC-specific transfection of mRNA/H 18 NPs and in vitro protein corona analysis of mRNA/H 18 NPs. (A) EGFP protein expression in splenic cell subsets of C57BL/6J mice 24 h post intravenous injection of different formulations. (B) The top 5 most abundant plasma proteins adsorbed on mRNA/H 18 NPs (C3: Complement C3; Ighm: Immunoglobulin heavy constant mu; Hbat1: Alpha-globin; Itih4: Inter alpha-trypsin inhibitor, heavy chain 4; Cnn2: Calponin). (C) Heatmap plot of major proteins in the protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. PBS group was used as a negative control. (D) Quantification of major adsorbed protein categories of different formulations. (E) Complement C3 abundance in protein corona adsorbed on mRNA/MC3-LNPs and mRNA/H 18 NPs. (F) Bioluminescence images of major organs and (G) Quantification of total bioluminescence flux in the spleen from C57BL/6J mice 6 h after intravenous injection of mLuc/H 18 NPs (mLuc dose of 0.25 mg kg −1 ). Mice were pre-treated with cobra venom factor (CVF) or PBS. (H) Fluorescence quantification of Cy5 mRNA delivered by uncoated or complement C3-coated Cy5-mRNA/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. (I) Bioluminescence intensity of luciferase protein translated from mRNA delivered by uncoated or complement C3-coated mLuc/H 18 NPs in BMDCs. BMDCs were pre-incubated with anti-CD11b (CR3) or anti-IgG blocking antibody. Data were shown as mean ± SD (n = 3).

    Article Snippet: Cobra venom factor (CVF) was purchased from TargetMol (MA, USA).

    Techniques: In Vivo, Transfection, In Vitro, Expressing, Injection, Clinical Proteomics, Negative Control, Combined Bisulfite Restriction Analysis Assay, Fluorescence, Incubation, Blocking Assay, Luciferase

    (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and Cobra venom factor (CVF) treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.

    Journal: bioRxiv

    Article Title: Neutrophils are critical for placental and fetal infection with the human pathogen Listeria monocytogenes

    doi: 10.64898/2026.03.16.712023

    Figure Lengend Snippet: (A) Percentage of blood cells positive for CFSE-labeled intracellular Lm obtained from peripheral blood of non-pregnant human adults exposed to CFSE-labeled Lm (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (B) Percentage of blood cells positive for CFSE-labeled intracellular Lm from isolated non-pregnant human peripheral blood cells exposed to CFSE-labeled Lm (mean±SEM, n=4 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (C) CFUs of intracellular Lm of Lm-infected lysed human neutrophils, PBMCs and platelets (mean±SEM, n=3 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (D) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after blocking c-Met and/or FcγR (mean±SEM, n=5 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). (E) Percentage of human non-pregnant neutrophils positive for intracellular CFSE-labeled Lm after serum treatment via heat inactivation (Hi) and Cobra venom factor (CVF) treatment. Neutrophils in Hank’s Balanced Salt Solution (HBSS) without Lm-infection served as control (mean±SEM, n=3-11 independent experiments, 1-way ANOVA, Tukey’s multiple comparison). *p <0.05, **p <0.01, ***p<0.001, ****p<0.0001.

    Article Snippet: Prior to Listeria opsonization, human serum was de-complemented using 12 μg of cobra venom factor (CVF) (Quidel, San Diego, USA) per 500 μl of extracted serum and incubated for 1 h at 37 °C ( ).

    Techniques: Labeling, Comparison, Isolation, Infection, Blocking Assay, Combined Bisulfite Restriction Analysis Assay, Control